Elanco reported strong Q3 2025 results, with 9% organic constant currency revenue growth, $1.137 billion in revenue, $198 million in adjusted EBITDA, and $0.19 in adjusted EPS.
The company raised its full-year 2025 guidance, now expecting organic constant currency growth of 6%-6.5%, adjusted EBITDA of $880 million-$900 million, and adjusted EPS of $0.91-$0.94.
Innovation revenue year-to-date reached $655 million, with full-year expectations raised to $840 million-$880 million; Credelio Quattro achieved blockbuster status with $100 million in net sales in less than eight months.
The net leverage ratio improved to 3.7x at quarter-end, and Elanco refinanced its $2.1 billion term loan B facility, extending maturities through 2032.

Nov 5, 2025, 1:00 PM

Transcript

Elanco Reports Strong Q3 2025 Results and Raises Full-Year Guidance

ELAN

Earnings

Guidance Update

Product Launch

Elanco reported strong Q3 2025 results, with 9% organic constant currency revenue growth to $1.137 billion, adjusted EBITDA of $198 million, and adjusted EPS of $0.19.
The company raised its full-year 2025 guidance, now anticipating organic constant currency revenue growth of 6-6.5%, adjusted EBITDA of $880 million-$900 million, and adjusted EPS of $0.91-$0.94.
Innovation revenue year-to-date reached $655 million, with the full-year expectation raised to $840 million-$880 million. Credelio Quattro achieved $100 million in net sales in less than eight months, and Experior grew 70% in Q3.
Elanco improved its net leverage ratio to 3.7 times at quarter end and refinanced its $2.1 billion term loan B facility, extending maturities through 2032.

Nov 5, 2025, 1:00 PM

Transcript

Elanco Reports Strong Q3 2025 Results and Raises Full-Year Guidance

ELAN

Earnings

Guidance Update

Revenue Acceleration/Inflection

Elanco reported strong Q3 2025 results, with 9% organic constant currency growth and $1.137 billion in revenue, exceeding guidance for revenue, adjusted EBITDA, and adjusted EPS.
The company raised its full-year 2025 outlook, now projecting organic constant currency growth of 6-6.5%, adjusted EBITDA of $880-$900 million, and adjusted EPS of $0.91-$0.94.
Full-year innovation revenue guidance was increased by $100 million at the midpoint to $840 million-$880 million, with Credelio Quattro reaching $100 million in net sales year-to-date through September.
Elanco improved its net leverage ratio to 3.7 times at quarter end and refinanced its $2.1 billion term loan B facility, extending maturities through 2032.
For 2026, the company expects margin expansion from the Elanco Ascend program and aims for a net leverage ratio under 3x longer term, despite an anticipated $15 million increase in interest expense.

Nov 5, 2025, 1:00 PM

Transcript

Elanco Animal Health Reports Strong Q3 2025 Results and Raises Full-Year Guidance

ELAN

Earnings

Guidance Update

Revenue Acceleration/Inflection

Elanco Animal Health reported strong Q3 2025 results, with revenue of $1,137 million, Adjusted EBITDA of $198 million, and Adjusted Diluted EPS of $0.19, all exceeding guidance ranges. The company achieved 9% organic constant currency revenue growth.
The company raised its full-year 2025 guidance, now expecting revenue between $4,645 million and $4,670 million, Adjusted EBITDA between $880 million and $900 million, and Adjusted Diluted EPS between $0.91 and $0.94.
Year-to-date innovation revenue contribution reached $655 million, with the 2025 target raised to $840-$880 million.
Elanco achieved a quarter-end net leverage ratio of 3.7x and improved its year-end target to 3.7x-3.8x, also successfully refinancing its 2027 Term Loan B.

Nov 5, 2025, 1:00 PM

Presentation

Elanco Animal Health Reports Strong Q3 2025 Results and Raises Full-Year Guidance

ELAN

Earnings

Guidance Update

Product Launch

Elanco Animal Health reported strong third quarter 2025 results, with revenue of $1,137 million, a 10% increase year-over-year, and Adjusted EPS of $0.19.
The company raised its full-year 2025 revenue guidance to $4,645 million to $4,670 million and its Adjusted EPS guidance to $0.91 to $0.94.
Elanco also improved its 2025 year-end net leverage ratio target to 3.7x to 3.8x and successfully completed the refinancing of its $2.1 billion Term Loan B debt facility.
Growth was driven by new products, with Credelio Quattro achieving $100 million in net sales in under eight months, and Experior and AdTab showing significant Q3 sales increases of approximately 70% and over 25% year-over-year, respectively.

Nov 5, 2025, 11:30 AM

8-K

Elanco Animal Health Reports Strong Q3 2025 Results and Raises Full-Year Outlook

ELAN

Earnings

Guidance Update

Revenue Acceleration/Inflection

Elanco Animal Health reported Q3 2025 revenue of $1,137 million, an increase of 10% year-over-year, with 9% organic constant currency growth.
For Q3 2025, the company posted an Adjusted Net Income of $94 million and Adjusted EPS of $0.19.
Elanco raised its full-year 2025 revenue guidance to $4,645 million to $4,670 million and its Adjusted EBITDA guidance to $880 million to $900 million.
The company improved its 2025 year-end net leverage ratio target to 3.7x to 3.8x, having already achieved 3.7x as of September 30, 2025.

Nov 5, 2025, 11:27 AM

Press Release

Elanco Animal Health Amends Credit Agreement and Secures New Loan Commitments

ELAN

Debt Issuance

New Projects/Investments

Elanco Animal Health Incorporated executed Amendment No. 3 to its Credit Agreement on October 31, 2025, to refinance existing term loans.
This amendment includes new commitments of $1,100,000,000 for 2025 Refinancing TLB Loans, €400,000,000.00 for 2025 Euro TLA Commitments, and $540,000,000 for 2025 Farm Credit Term Loan Commitments.
The Credit Agreement also modified investment limitations, increasing the aggregate outstanding amount for general investments to the greater of $600,000,000 and 0.60 times EBITDA (previously 0.50 times EBITDA), and for joint venture investments to the greater of $180,000,000 and 0.21 times EBITDA (previously 0.15 times EBITDA).

Nov 3, 2025, 12:30 PM

8-K

Elanco Announces Label Expansion for Credelio Quattro and Credelio

ELAN

Product Launch

New Projects/Investments

Elanco Animal Health announced on October 27, 2025, that the FDA approved expanded labels for its canine parasiticides, Credelio Quattro and Credelio.
The expanded labels now include prevention of Lyme disease as a direct result of killing black-legged ticks and treatment and control of longhorned tick infestations.
This expansion addresses a growing market need, with over 422,000 cases of Lyme disease in dogs recorded so far this year, surpassing the total for all of 2019, and the longhorned tick rapidly spreading across 22 states.

Oct 27, 2025, 10:27 AM

Press Release

Elanco Receives FDA Emergency Use Authorization for Dog Screwworm Treatment

ELAN

Product Launch

Elanco Animal Health has received the first-ever Emergency Use Authorization (EUA) from the U.S. FDA for its Credelio tablets to treat New World screwworm infestations in dogs.
This authorization addresses a re-emerging threat, as the screwworm parasite, previously eradicated from the U.S., has been detected near the southern border.
Credelio, an existing flea and tick control drug, demonstrated 100% efficacy in clearing screwworm larvae within 24 hours in a small study, though the authorization is temporary and potential side effects include tremors and seizures.

Oct 25, 2025, 1:24 AM

Morningstar

Elanco Receives FDA Emergency Use Authorization for Credelio in Dogs

ELAN

Product Launch

New Projects/Investments

Elanco Animal Health has secured the first-ever FDA Emergency Use Authorization (EUA) for its product Credelio™ (lotilaner) to treat New World screwworm (NWS) infestations in dogs.
This authorization provides a critical, ready-now treatment option for veterinarians and pet owners, as NWS cases have been confirmed less than 70 miles south of the U.S.-Mexico border.
The EUA is supported by a study demonstrating 100% efficacy of Credelio against NWS larvae within 24 hours in naturally infested dogs.
While Credelio is not specifically approved for NWS treatment, it is approved for other uses like flea and tick control, which is important for preventing NWS infestations.

Oct 24, 2025, 8:55 PM

Press Release

Filings & Transcripts

View All Documents

Recent SEC filings and earnings call transcripts for ELAN.

No recent filings or transcripts found for ELAN.